Copyright: ©Author(s) 2026. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution-NonCommercial (CC BY-NC 4.0) license. No commercial re-use. See permissions. Published by Baishideng Publishing Group Inc.
World J Cardiol. Oct 26, 2026; 18(10): 125443
Published online Oct 26, 2026. doi: 10.4330/wjc.125443
Published online Oct 26, 2026. doi: 10.4330/wjc.125443
Evolving role of cardiac magnetic resonance in cardiac amyloidosis
Farhan Ashraf, Department of Cardiology, LifeCore Private Clinic, Abu Dhabi 68311, United Arab Emirates
Author contributions: Ashraf F conceived the idea for the review, did the literature search, wrote and edited the manuscript.
AI contribution statement: An AI assistant (Claude, Anthropic PBC) was used in preparing this manuscript for the following purposes: Support for literature screening and identification of candidate references for manual retrieval; language editing and refinement of the author's draft text; and assistance with the structure and layout of Tables 1, 2 and 3. It was not used to generate original scientific claims, to analyse data, or to produce content not subsequently checked against primary sources. The author retrieved and read in full every source cited, individually verified every reference against PubMed for bibliographic details, publication status, PMID and DOI. The author takes full responsibility for the scientific content, accuracy, evidence summaries, numerical claims, conclusions and integrity of the manuscript.
Conflict-of-interest statement: The author declares no conflict of interests for this article.
Corresponding author: Farhan Ashraf, MD, Director, Department of Cardiology, LifeCore Private Clinic, 13 Al Halawi St - Al Muntazah - Ministries Complex, Abu Dhabi 68311, United Arab Emirates. faht47@hotmail.com
Received: July 7, 2026
Revised: September 6, 2026
Accepted: October 8, 2026
Published online: October 26, 2026
Processing time: 108 Days and 16 Hours
Revised: September 6, 2026
Accepted: October 8, 2026
Published online: October 26, 2026
Processing time: 108 Days and 16 Hours
Core Tip
Core Tip: Cardiac magnetic resonance imaging role in cardiac amyloidosis has evolved over time. Initially, cine imaging, chamber quantification, and characteristic delayed enhancement findings were used to identify this condition. With evolving technology, T1, T2 mapping and extra cellular volume have added to diagnostic accuracy. Further data has shown potential of differentiating transthyretin amyloidosis from amyloid light-chain amyloidosis. Extracellular volume and delayed enhancement imaging carry robust prognostic information, and serial extracellular volume is under active investigation as a treatment-monitoring biomarker.